These guidelines were issued because these drugs have only been through phase-2b trials and studies for safety and efficacy. The interim guidelines recommend that use of these drugs in the treatment regimen of MDR-TB be made, subject to the conditions that include proper patient inclusion, adherence to the principles of designing a WHO-recommended MDR-TB regimen, treatment is closely monitored with active pharmaco vigilance and proper management of adverse drug reactions and prevention of drug-drug interaction. The conditions also include that patient's must be informed consent be obtained.
According to the Annual WHO Global TB Reports, the estimated proportion of multidrug resistant tuberculosis (MDR-TB) cases among new cases in India has been 2.1 percent, 2.2 percent and 2.2 percent in years 2011, 2012 and 2013, respectively. These proportions are much less than high MDR-TB burden countries.
Meanwhile the government has informed that it is receiving financial assistance in the form of loans and grants from various foreign agencies / countries, including the World Bank, for funding projects to strengthen health sector in the country.
The WHO does not directly assist health programmes / projects of the central / state governments. The assistance received from various foreign agencies / countries is utilized for specific projects including Immunization Programme, National Vector Borne Disease Control Programme, Reproductive and Child Health-II Programme, Revised National Tuberculosis Control Programme, National Leprosy Eradication Programme, HIV/AIDS Control Programmes, and various projects meant for strengthening of health systems in the states.
Stay updated on the go with The Times of India’s mobile apps. Click here to download it for your device.
0 comments:
Post a Comment